| Biosimilars: Global Markets (BIO090E) |
| Idacio (Adalimumab) |
|
It is a biosimilar to Humira; Idacio treats several autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and psoriasis. It offers comparable safety and efficacy to the reference product, making it a cost-effective alternative for chronic inflammatory conditions. |
| Tyenne (tocilizumab) |
|
Tyenne, a biosimilar to Actemra, is a prescription medication that acts as an Interleukin-6 (IL-6) receptor antagonist. It treats several autoimmune diseases, comprising rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and polyarticular juvenile idiopathic arthritis. |
| Stimufend (pegfilgrastim) |
|
Stimufend, a biosimilar to Neulasta, is a leukocyte growth factor used to decrease the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies who are undergoing myelosuppressive anti-cancer treatments that have a clinically significant risk of causing febrile neutropenia. |
|
